Literature DB >> 36008617

Mycobacterium abscessus pathogenesis identified by phenogenomic analyses.

Lucas Boeck1,2,3,4, Sophie Burbaud1,2, Marcin Skwark5, Will H Pearson6,7, Jasper Sangen1,2, Andreas W Wuest4, Eleanor K P Marshall6,7, Aaron Weimann1,2, Isobel Everall3, Josephine M Bryant1,2, Sony Malhotra5,8, Bridget P Bannerman1,2,5, Katrin Kierdorf6,7,9, Tom L Blundell5, Marc S Dionne6,7, Julian Parkhill10, R Andres Floto11,12,13.   

Abstract

The medical and scientific response to emerging and established pathogens is often severely hampered by ignorance of the genetic determinants of virulence, drug resistance and clinical outcomes that could be used to identify therapeutic drug targets and forecast patient trajectories. Taking the newly emergent multidrug-resistant bacteria Mycobacterium abscessus as an example, we show that combining high-dimensional phenotyping with whole-genome sequencing in a phenogenomic analysis can rapidly reveal actionable systems-level insights into bacterial pathobiology. Through phenotyping of 331 clinical isolates, we discovered three distinct clusters of isolates, each with different virulence traits and associated with a different clinical outcome. We combined genome-wide association studies with proteome-wide computational structural modelling to define likely causal variants, and employed direct coupling analysis to identify co-evolving, and therefore potentially epistatic, gene networks. We then used in vivo CRISPR-based silencing to validate our findings and discover clinically relevant M. abscessus virulence factors including a secretion system, thus illustrating how phenogenomics can reveal critical pathways within emerging pathogenic bacteria.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36008617      PMCID: PMC9418003          DOI: 10.1038/s41564-022-01204-x

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   30.964


  53 in total

1.  Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study.

Authors:  Byung Woo Jhun; Seong Mi Moon; Kyeongman Jeon; O Jung Kwon; Heejin Yoo; Keumhee C Carriere; Hee Jae Huh; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Eur Respir J       Date:  2020-01-02       Impact factor: 16.671

2.  Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infections in Queensland, Australia 2001-2016.

Authors:  Rachel M Thomson; Luis Furuya-Kanamori; Cushla Coffey; Scott C Bell; Luke D Knibbs; Colleen L Lau
Journal:  Sci Total Environ       Date:  2020-06-13       Impact factor: 7.963

3.  Outcome according to subspecies following lung transplantation in cystic fibrosis pediatric patients infected with Mycobacterium abscessus.

Authors:  Ema Kavaliunaite; Kathryn A Harris; Paul Aurora; Garth Dixon; Delane Shingadia; Nagarajan Muthialu; Helen Spencer
Journal:  Transpl Infect Dis       Date:  2020-03-18       Impact factor: 2.228

4.  Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis.

Authors:  Charles R Esther; Denise A Esserman; Peter Gilligan; Alan Kerr; Peadar G Noone
Journal:  J Cyst Fibros       Date:  2010-01-13       Impact factor: 5.482

Review 5.  Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.

Authors:  Matt D Johansen; Jean-Louis Herrmann; Laurent Kremer
Journal:  Nat Rev Microbiol       Date:  2020-02-21       Impact factor: 60.633

6.  Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Authors:  Josephine M Bryant; Dorothy M Grogono; Daniela Rodriguez-Rincon; Isobel Everall; Karen P Brown; Pablo Moreno; Deepshikha Verma; Emily Hill; Judith Drijkoningen; Peter Gilligan; Charles R Esther; Peadar G Noone; Olivia Giddings; Scott C Bell; Rachel Thomson; Claire E Wainwright; Chris Coulter; Sushil Pandey; Michelle E Wood; Rebecca E Stockwell; Kay A Ramsay; Laura J Sherrard; Timothy J Kidd; Nassib Jabbour; Graham R Johnson; Luke D Knibbs; Lidia Morawska; Peter D Sly; Andrew Jones; Diana Bilton; Ian Laurenson; Michael Ruddy; Stephen Bourke; Ian Cjw Bowler; Stephen J Chapman; Andrew Clayton; Mairi Cullen; Thomas Daniels; Owen Dempsey; Miles Denton; Maya Desai; Richard J Drew; Frank Edenborough; Jason Evans; Jonathan Folb; Helen Humphrey; Barbara Isalska; Søren Jensen-Fangel; Bodil Jönsson; Andrew M Jones; Terese L Katzenstein; Troels Lillebaek; Gordon MacGregor; Sarah Mayell; Michael Millar; Deborah Modha; Edward F Nash; Christopher O'Brien; Deirdre O'Brien; Chandra Ohri; Caroline S Pao; Daniel Peckham; Felicity Perrin; Audrey Perry; Tania Pressler; Laura Prtak; Tavs Qvist; Ali Robb; Helen Rodgers; Kirsten Schaffer; Nadia Shafi; Jakko van Ingen; Martin Walshaw; Danie Watson; Noreen West; Joanna Whitehouse; Charles S Haworth; Simon R Harris; Diane Ordway; Julian Parkhill; R Andres Floto
Journal:  Science       Date:  2016-11-11       Impact factor: 47.728

7.  Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study.

Authors:  Josephine M Bryant; Dorothy M Grogono; Daniel Greaves; Juliet Foweraker; Iain Roddick; Thomas Inns; Mark Reacher; Charles S Haworth; Martin D Curran; Simon R Harris; Sharon J Peacock; Julian Parkhill; R Andres Floto
Journal:  Lancet       Date:  2013-03-29       Impact factor: 79.321

8.  Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.

Authors:  Tavs Qvist; David Taylor-Robinson; Elisabeth Waldmann; Hanne Vebert Olesen; Christine Rønne Hansen; Inger Hee Mathiesen; Niels Høiby; Terese L Katzenstein; Rosalind L Smyth; Peter J Diggle; Tania Pressler
Journal:  J Cyst Fibros       Date:  2015-10-09       Impact factor: 5.482

9.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

10.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.